Kinnate Updates on Monotherapy Dose Escalation from Global Phase 1

 

• KIN-2787 cleared the predicted efficacious dose at 300 mg bid; dose escalation continues with maximum tolerated dose not yet determined
   
• KIN-2787 achieved meaningful exposures that were dose proportional and exceeded the predicted efficacious thresholds based on preclinical models
   
• Observed encouraging initial clinical responses with KIN-2787 thus far
   
• Company anticipates sharing detailed dose escalation data in the first half of 2023
   
• Approximately $262 million cash on hand as of September 30, 2022; cash runway into mid-2024

https://www.biospace.com/article/releases/kinnate-biopharma-inc-announces-recent-corporate-updates-including-on-the-ongoing-kin-2787-monotherapy-dose-escalation-from-global-phase-1-trial/